EUCTR2010-018340-14-GB进行中（未招募）1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-D
niversity of Nottingham0 个研究点目标入组 136 人开始时间: 2010年10月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1) Male or Female patients aged 18-75 years able to give informed consent.
- •2) Patients should all have had a colonoscopy or sigmoidoscopy within the last 12 months to exclude microscopic or any inflammatory colitis. (If not, but they have had a negative colonoscopy within 5 years and symptoms are unchanged, then a sigmoidoscopy and mucosal biopsy of the left colon would be sufficient to exclude microscopic or any inflammatory colitis).
- •3) IBS-D Patients meeting Rome III criteria prior to screening phase.
- •4) Patients with =25% soft (score >4) and <25% hard (score 1 or 2) stools during the screening phase, as scored by the daily symptom and stool diary*.
- •5) Patients with a stool frequency of 3 or more per day for 2 days or more per week during the screening phase*.
- •6) Satisfactory completion of the daily stool and symptom diary during the screening phase at the discretion of the investigator.
- •7) Women of child bearing potential willing and able to use at least one highly effective contraceptive method throughout the study. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as: implants, injectables, combined oral contraceptives, sexual abstinence or vasectomised partner.
- •*If inclusion criterion 4 and/or 5 is/are not met but the results are considered atypical (as observed from medical history and patient recall) then the patient can be re-screen on 1 occasion only.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Women who are pregnant or breast feeding
- •2)Prior abdominal surgery which may cause bowel symptoms similar to IBS (note appendectomy and cholecystectomy will not be an exclusion)
- •3)Patients unable to stop anti-muscarinics, anti-spasmodics, high dose tricyclic antidepressants (i.e. above 50 mg/day), opiates / anti-diarrhoeal drugs*, NSAIDs (occasional over the counter use and topical formulations are allowed), long-term antibiotics, other anti-inflammatory drugs or 5-ASA containing drugs.
- •4)Patients on selective serotonin re-uptake inhibitors and low dose tricyclic antidepressants (i.e. up to 50 mg/day) for at least 3 months previous unwilling to remain on a stable dose for the duration of the trial.
- •5)Patients with other gastro-intestinal diseases including colitis and Crohn’s disease.
- •6)Patients with the following conditions: Renal impairment, severe hepatic impairment or salicylate hypersensitivity.
- •7)Patients currently participating in another trial or have been in a trial within the previous 3 months
- •8)Patients who in the opinion of the investigator are considered unsuitable due to inability to comply with instructions
- •9)Patients with serious concomitant diseases e.g. cardiovascular, respiratory, neurological etc.
- •*Loperamide is allowed as rescue medication through-out the trial, however if >2 doses / week are taken during the screening phase then they are not eligible, though they can be re-screened on 1 occasion only.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
已完成
2 期
Mesalazine in chronic idiopathic urticariaChronic Idiopathic urticaria.Idiopathic UrticariaIRCT138710041520N1Shiraz University of Medical Sciences - Vice Chancellor for Research Affairs30
已完成
不适用
Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by non-steroidal anti-inflammatory drugs(NSAIDs).Patients with rheumatoid arthritis with anemia taking NSAIDsJPRN-UMIN000005362Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine13
已完成
4 期
Mesalazine for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D)Irritable bowel syndromeISRCTN76612274niversity of Nottingham (UK)108
已完成
4 期
Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)Irritable Bowel Syndrome With DiarrhoeaNCT01316718University of Nottingham108